ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SLP Simulations Plus Inc

44.69
-0.96 (-2.10%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Simulations Plus Inc NASDAQ:SLP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.96 -2.10% 44.69 42.91 50.00 45.75 44.64 45.69 79,538 00:12:29

Simulations Plus to Present at Oppenheimer Healthcare Conference

09/03/2021 1:30pm

Business Wire


Simulations Plus (NASDAQ:SLP)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Simulations Plus Charts.

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, will be presenting at Oppenheimer’s 31st Annual Healthcare Conference on Tuesday, March 16, 2021. Mr. O’Connor’s presentation, which will be webcast live, will begin at 2:30 p.m. ET. In addition, Mr. O’Connor and chief financial officer Will Frederick will host one-on-one meetings throughout the day.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the presentation. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our vision is to improve health through innovative solutions, and our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science-based software and consulting solutions that optimize treatment options and improve patient lives. For more information, please visit our website at www.simulations-plus.com.

Simulations Plus Investor Relations Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com

Hayden IR Mr. Cameron Donahue 651-653-1854 slp@haydenir.com

1 Year Simulations Plus Chart

1 Year Simulations Plus Chart

1 Month Simulations Plus Chart

1 Month Simulations Plus Chart

Your Recent History

Delayed Upgrade Clock